The surgeon's corner

What is the evidence allowing us to state that transcatheter aortic valve replacement via the femoral artery is a more attractive option compared to transapical valve replacement?

EuroIntervention 2011;7:903-904. DOI: 10.4244/EIJV7I8A143

Arie Pieter Kappetein
A. Pieter Kappetein1*, MD, PhD; Stuart J. Head1, MS; Hendrik Treede2, MD; Hermann Reichenspurner2, MD, PhD; Friedrich W. Mohr3, MD, PhD; Thomas Walther4, MD, PhD
1. Department of Cardio-Thoracic Surgery, Erasmus University Medical Center, Rotterdam, The Netherlands; 2. Department of Cardiovascular Surgery, University Heart Center, Hamburg, Germany; 3. Deparment of Cardiac Surgery, Heart Center,
Recently, transcatheter aortic valve replacement (TAVR) has been shown to result in similar 12-month survival as surgical aortic valve replacement (SAVR) for high-risk patients with severe aortic stenosis1. For patients deemed inoperable TAVR showed a 20% survival benefit at one year compared to medical treatment2.

The PARTNER Trial

During the focused late-breaking clinical trial session at TCT in San Francisco new data on TAVR were presented. Good news came from the PARTNER B trial which tested TAVR with the SAPIEN device (Edwards Lifesciences, Irvine, CA, USA) in inoperable patients against best medical care. Data showed that survival curves are ...

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article
Radial access in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty in acute myocardial infarction: the HORIZONS-AMI trial

Latest news